Biocon And Viatris Ready To Launch EU Bevacizumab
Biocon Biologics Announces Formal EU Approval For Abevmy Biosimilar
Executive Summary
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
You may also be interested in...
Biocon Gets FDA Observations At Key Biosimilars Facilities
Biocon has revealed that an FDA inspection of key biosimilars manufacturing facilities in Bengaluru and Malaysia in August has resulted in numerous Form 483 observations across three Biocon Biologics sites.
Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
Viatris And Biocon Launch Bevacizumab Biosimilar In Canada
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.